Trial · NCT03906292
Frontline Asciminib Combination in Chronic Phase CML
NCT03906292, Phase 2, Active not recruiting, University of Jena
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Frontline Asciminib Combination in Chronic Phase CML. Trials, record NCT03906292. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03906292
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Frontline Asciminib Combination in Chronic Phase CML
- NCT number
- NCT03906292
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 125 participants, actual
- Lead sponsor
- University of Jena
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Imatinib, Nilotinib 300 mg, Dasatinib, Asciminib
- First posted
- 2019-04-08
- Last updated
- 2026-08-18
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | deep molecular response (Rate of MR4) | at month 12 after Start of Standard-Therapy | Achievement of deep molecular response (MR4) throught standardized testing of BCR-ABL-transcript Levels |
| Primary | deep molecular Response (Rate of MR4.5) | at month 36 after Start of Standard-Therapy | Achievement of deep molecular response (MR4.5) throught standardized testing of BCR-ABL-transcript Levels |
| Secondary | molecular response (MMR and MR4.5) | at and by 6, 12, 18, 24, 36 and 60 months after Start of Therapy | Achievement of deep molecular response throught standardized testing of BCR-ABL-transcript levels |
| Secondary | Adverse Events | at and by baseline, 3, 6, 12, 15, 18, 21, 24, 36 and 60 months after Start of Therapy | Incidence of adverse events grade 1-5 and 3-5 |
| Secondary | Progression free survival | at month 60 after Start of Therapy | Progression free survival at the end of the study |
| Secondary | Overall survival | at month 60 after Start of Therapy | Overall survival at the end of the study |
| Secondary | Maintenance of MR4.5 during Asciminib-monotherapy | at month 36 and 60 after Start of Therapy | Achievement of deep molecular response (MR4.5) throught standardized testing of BCR-ABL-transcript Levels |
| Secondary | Achievement and durability of treatment-free remission | months 37 and 60 after Start of Therapy | Achievement of deep molecular response (MR4) throught standardized testing of BCR-ABL-transcript Levels |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03906292
GET https://conductscience.org/api/trials/v1/NCT03906292/registered